My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 98

    1.

    Tooth discoloration in patients with neonatal diabetes after transfer onto glibenclamide: a previously unreported side effect.

    Kumaraguru J, Flanagan SE, Greeley SA, Nuboer R, Støy J, Philipson LH, Hattersley AT, Rubio-Cabezas O.

    Diabetes Care. 2009 Aug;32(8):1428-30. Epub 2009 May 12.PMID: 19435956 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

    Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT; Neonatal Diabetes International Collaborative Group.

    N Engl J Med. 2006 Aug 3;355(5):467-77.PMID: 16885550 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.

    Bremer AA, Ranadive S, Lustig RH.

    Pediatr Diabetes. 2008 Jun;9(3 Pt 1):236-9. Epub 2008 Jan 24.PMID: 18221420 [PubMed - indexed for MEDLINE]Related articles

    4.

    Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.

    Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ.

    Diabetologia. 2006 Nov;49(11):2559-63. Epub 2006 Sep 19.PMID: 17047922 [PubMed - indexed for MEDLINE]Related articles

    5.

    Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.

    Flechtner I, de Lonlay P, Polak M.

    Diabetes Metab. 2006 Dec;32(6):569-80. Review.PMID: 17296510 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.

    Kim MS, Kim SY, Kim GH, Yoo HW, Lee DW, Lee DY.

    J Korean Med Sci. 2007 Aug;22(4):616-20.PMID: 17728498 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers.

    Stanik J, Gasperikova D, Paskova M, Barak L, Javorkova J, Jancova E, Ciljakova M, Hlava P, Michalek J, Flanagan SE, Pearson E, Hattersley AT, Ellard S, Klimes I.

    J Clin Endocrinol Metab. 2007 Apr;92(4):1276-82. Epub 2007 Jan 9.PMID: 17213273 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.

    Della Manna T, Battistim C, Radonsky V, Savoldelli RD, Damiani D, Kok F, Pearson ER, Ellard S, Hattersley AT, Reis AF.

    Arq Bras Endocrinol Metabol. 2008 Nov;52(8):1350-5.PMID: 19169493 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.

    Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT; Neonatal Diabetes International Collaborative Group.

    Diabetes Care. 2008 Feb;31(2):204-9. Epub 2007 Nov 19.PMID: 18025408 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Transition from insulin to glyburide in a 4-month-old girl with neonatal diabetes mellitus caused by a mutation in KCNJ11.

    Chan YM, Laffel LM.

    Pediatr Diabetes. 2007 Aug;8(4):235-8.PMID: 17659066 [PubMed - indexed for MEDLINE]Related articles

    11.

    The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.

    Koster JC, Cadario F, Peruzzi C, Colombo C, Nichols CG, Barbetti F.

    J Clin Endocrinol Metab. 2008 Mar;93(3):1054-61. Epub 2007 Dec 11.PMID: 18073297 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.

    Tonini G, Bizzarri C, Bonfanti R, Vanelli M, Cerutti F, Faleschini E, Meschi F, Prisco F, Ciacco E, Cappa M, Torelli C, Cauvin V, Tumini S, Iafusco D, Barbetti F; Early-Onset Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetology.

    Diabetologia. 2006 Sep;49(9):2210-3. Epub 2006 Jul 1. No abstract available. PMID: 16816952 [PubMed - indexed for MEDLINE]Related articles

    13.

    Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.

    Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njølstad PR, Ashcroft FM, Hattersley AT.

    N Engl J Med. 2004 Apr 29;350(18):1838-49. Erratum in: N Engl J Med. 2004 Sep 30;351(14):1470. PMID: 15115830 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.

    Shimomura K, Hörster F, de Wet H, Flanagan SE, Ellard S, Hattersley AT, Wolf NI, Ashcroft F, Ebinger F.

    Neurology. 2007 Sep 25;69(13):1342-9. Epub 2007 Jul 25.PMID: 17652641 [PubMed - indexed for MEDLINE]Related articles

    15.

    Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity.

    Malecki MT, Skupien J, Klupa T, Wanic K, Mlynarski W, Gach A, Solecka I, Sieradzki J.

    Diabetes Care. 2007 Jan;30(1):147-9. No abstract available. Erratum in: Diabetes Care. 2007 Feb;30(2):455. PMID: 17192350 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.

    Zung A, Glaser B, Nimri R, Zadik Z.

    J Clin Endocrinol Metab. 2004 Nov;89(11):5504-7.PMID: 15531505 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype.

    Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT.

    Diabetologia. 2006 Jun;49(6):1190-7. Epub 2006 Apr 12.PMID: 16609879 [PubMed - indexed for MEDLINE]Related articles

    18.

    Familial permanent neonatal diabetes with KCNJ11 mutation and the response to glyburide therapy--a three-year follow-up.

    Begum-Hasan J, Polychronakos C, Brill H.

    J Pediatr Endocrinol Metab. 2008 Sep;21(9):895-903.PMID: 18924582 [PubMed - indexed for MEDLINE]Related articles

    19.

    Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.

    Mlynarski W, Tarasov AI, Gach A, Girard CA, Pietrzak I, Zubcevic L, Kusmierek J, Klupa T, Malecki MT, Ashcroft FM.

    Nat Clin Pract Neurol. 2007 Nov;3(11):640-5.PMID: 17982434 [PubMed - indexed for MEDLINE]Related articles

    20.

    Variable phenotypic spectrum of diabetes mellitus in a family carrying a novel KCNJ11 gene mutation.

    D'Amato E, Tammaro P, Craig TJ, Tosi A, Giorgetti R, Lorini R, Ashcroft FM.

    Diabet Med. 2008 Jun;25(6):651-6.PMID: 18544102 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity